Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 19/20 | 0.54 |
| ▸ | SMARCA2 | P51531 | 18/20 | 0.54 |
| ▸ | SMARCA4 | P51532 | 18/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 10/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30520304 | 0.88 | SMARCA2 (0.50) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL25345477 | 0.88 | SMARCA2 (0.50) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL20009090 | 0.85 | SMARCA2 (0.71) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL30606905 | 0.85 | SMARCA2 (0.71) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL23772810 | 0.84 | PBRM1 (0.49) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL23751589 | 0.84 | PBRM1 (0.73) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL25347731 | 0.82 | SMARCA2 (0.50) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL30520235 | 0.82 | SMARCA2 (0.50) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL18038859 | 0.81 | PBRM1 (0.66) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL30606896 | 0.81 | PBRM1 (0.66) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | AURIGENE DISCOVERY TECH LTD (IN) | 2025-07-29 | — | — | US | disclosed |
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | Aurigene Oncology Technologies Limited (IN) | 2024-08-15 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| CN-112771038-A | Pyridazine derivatives as SMARCA2/4 degradants | 奥里吉恩发现科技有限公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-3784665-A1 | PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS | Aurigene Discovery Technologies Limited (IN) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | PBRM1 37/4885SMARCA2 3/4885SMARCA4 5/4885 |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | SMARCC1, SMARCC2, SMARCA2 | PBRM1 37/4885SMARCA2 3/4885SMARCA4 5/4885 |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | PBRM1 37/4885SMARCA2 3/4885SMARCA4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.